Status and phase
Conditions
Treatments
About
In patients with oligometastatic (1-5 lesions) extensive-stage small cell lung cancer, to explore the efficacy and safety of Durvalumab immunotherapy combined with chemotherapy followed by consolidation radiotherapy, to provide scientific basis for the formulation of the best comprehensive treatment plan in the future.
Full description
To explore the efficacy and safety of consolidation radiotherapy after Durvalumab immunotherapy combined with chemotherapy in patients with oligometastatic small cell lung cancer (1-5 lesions), so as to provide scientific basis for making the best comprehensive treatment plan in the future.All subjects will receive the following treatments:
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
58 participants in 1 patient group
Loading...
Central trial contact
liao zhiwei
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal